Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Shelton Capital Management

Shelton Capital Management reduced its position in Exelixis, Inc. (NASDAQ:EXELFree Report) by 4.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,977 shares of the biotechnology company’s stock after selling 720 shares during the period. Shelton Capital Management’s holdings in Exelixis were worth $305,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Fifth Third Bancorp increased its position in shares of Exelixis by 100.9% in the second quarter. Fifth Third Bancorp now owns 1,366 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 686 shares in the last quarter. Altshuler Shaham Ltd purchased a new stake in shares of Exelixis in the second quarter worth about $28,000. Massmutual Trust Co. FSB ADV raised its holdings in shares of Exelixis by 189.7% during the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 1,440 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 943 shares during the period. CENTRAL TRUST Co acquired a new position in Exelixis during the 2nd quarter worth approximately $34,000. Finally, Parallel Advisors LLC boosted its holdings in Exelixis by 52.8% in the 2nd quarter. Parallel Advisors LLC now owns 1,809 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 625 shares during the period. Hedge funds and other institutional investors own 93.09% of the company’s stock.

Insider Activity at Exelixis

In other Exelixis news, EVP Dana Aftab sold 4,600 shares of the business’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $22.47, for a total transaction of $103,362.00. Following the completion of the transaction, the executive vice president now owns 399,943 shares in the company, valued at approximately $8,986,719.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on EXEL shares. HC Wainwright assumed coverage on shares of Exelixis in a report on Tuesday, September 26th. They set a “buy” rating and a $28.00 price target for the company. TheStreet cut Exelixis from a “b” rating to a “c+” rating in a research note on Monday, October 9th. SVB Securities started coverage on Exelixis in a research note on Tuesday, August 8th. They set a “market perform” rating and a $18.00 price objective for the company. Truist Financial reiterated a “buy” rating and set a $32.00 target price on shares of Exelixis in a research note on Wednesday, September 13th. Finally, Oppenheimer lifted their price target on shares of Exelixis from $25.00 to $29.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 22nd. Five research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $25.44.

Check Out Our Latest Research Report on EXEL

Exelixis Stock Performance

Shares of EXEL opened at $20.93 on Tuesday. The firm has a fifty day moving average of $21.28 and a 200-day moving average of $20.48. The company has a market cap of $6.51 billion, a price-to-earnings ratio of 74.75, a price-to-earnings-growth ratio of 1.16 and a beta of 0.59. Exelixis, Inc. has a 1 year low of $15.32 and a 1 year high of $22.80.

Exelixis (NASDAQ:EXELGet Free Report) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.07). The firm had revenue of $471.90 million for the quarter, compared to analyst estimates of $473.31 million. Exelixis had a net margin of 5.19% and a return on equity of 3.71%. The company’s revenue for the quarter was up 14.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.23 earnings per share. Analysts predict that Exelixis, Inc. will post 0.62 EPS for the current year.

Exelixis Company Profile

(Free Report)

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Read More

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.